Review



human bladder carcinoma sw780 (grade i) cells  (Procell Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Procell Inc human bladder carcinoma sw780 (grade i) cells
    MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells <t>SW780</t> and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.
    Human Bladder Carcinoma Sw780 (Grade I) Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+bladder+carcinoma+sw780+(grade+i)+cells/sw780/pmc09667867-77-0-22
    Average 90 stars, based on 1 article reviews
    human bladder carcinoma sw780 (grade i) cells - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction"

    Article Title: Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.1016542

    MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells SW780 and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.
    Figure Legend Snippet: MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells SW780 and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.

    Techniques Used: Gene Expression, Biomarker Discovery, Expressing, Immunohistochemistry



    Similar Products

    human bladder carcinoma sw780 (grade i) cells  (Procell Inc)
    90
    Procell Inc human bladder carcinoma sw780 (grade i) cells
    MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells <t>SW780</t> and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.
    Human Bladder Carcinoma Sw780 (Grade I) Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+bladder+carcinoma+sw780+(grade+i)+cells/sw780/pmc09667867-77-0-22
    Average 90 stars, based on 1 article reviews
    human bladder carcinoma sw780 (grade i) cells - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells SW780 and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.

    Journal: Frontiers in Oncology

    Article Title: Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction

    doi: 10.3389/fonc.2022.1016542

    Figure Lengend Snippet: MAP1A gene expression and prognosis validation. (A) Validation of MAP1A expression in bladder cancer tissue samples and normal tissue samples using the GEPIA database and the GETx database. (B) MAP1A expression in bladder cancer cells SW780 and 5637, as well as normal bladder epithelial cells SV-HUC-1. (C) MAP1A in the GEPIA database for overall survival analysis of bladder cancer. (D) MAP1A correlation with disease-free survival in bladder cancer (GEPIA database). (E) MAP1A expression in bladder cancer tissues (immunohistochemistry, HPA database). (F) MAP1A expression in pan-cancer. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001). BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck cancer; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma. (G) The expression of MAP1A in different stage of bladder cancer.

    Article Snippet: Human bladder carcinoma SW780 (Grade I) and 5637 (Grade II) cells, as well as human bladder epithelial cell SV-HUC-1, were obtained from Procell Life Science & Technology Co., Ltd. (Wuhan, China).

    Techniques: Gene Expression, Biomarker Discovery, Expressing, Immunohistochemistry